Efficacy and safety of 1 year treatment with Liraglutide in subjects with type 2 diabetes

Flavia Prodam; Marco Zavattaro; Chantal Ponziani; Loredana Pagano; Marina Caputo; Gabriele Allochis; Sama Maria Teresa; Arianna Busti; Gianluca Aimaretti

doi:10.1530/endoabs.32.P467

P467

Prev Next

Section Contents Cite

Endocrine Abstracts (2013) 32 P467 | DOI: 10.1530/endoabs.32.P467

ECE2013 Poster Presentations Diabetes (151 abstracts)

Efficacy and safety of 1 year treatment with Liraglutide in subjects with type 2 diabetes

Flavia Prodam ^1, , Marco Zavattaro ² , Chantal Ponziani ² , Loredana Pagano ² , Marina Caputo ² , Gabriele Allochis , Samà Maria Teresa ² , Arianna Busti ² & Gianluca Aimaretti ²

Err

Author affiliations

¹Department of Health Sciences, Novara, Italy; ²Department of Translational Medicine, Novara, Italy.

Introduction: Liraglutide, a GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the efficacy and safety of liraglutide in daily clinical practice in a heterogeneous population with DM2.

Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). All patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatment, or patients intolerant to metformin were recruited. Exclusion criteria were: the presence of kidney diseases on dialysis, lack of compliance or refusal to injective therapy. Changes in glucose, HbA1c, body weight, BMI and lipid profile were primary outcomes. Adverse events and drop-out rate were evaluated.

Results: 243 subjects (110 males and 133 females) were recruited, with an age of (mean±S.D.) 59.6±10.4 years and a disease duration of 8.3±7.0 years. Fasting blood glucose (10.3±3.1 vs 8.4±2.6 mmol/l, P<0.0001) and HbA1c (8.6±1.3 vs 7.4±1.0%, P<0.0001) decreased at 4 months and maintained a plateau overtime. Body weight (92.8±18.9 vs 89.5±18.2 kg, P<0.0001) and BMI (33.8±6.6 vs 32.3±6.0 kg/m², P<0.0001) decreased at 4 months and then remained stable. Lipids slightly decreased over time. Total cholesterol (4.6±0.9 vs 4.3±0.9 mmol/l, P<0.01), LDL-cholesterol (2.6±0.8 vs 2.4±0.7 mmol/l, P<0.03) and triglycerides (1.9±1.0 vs 1.7±0.9 mmol/l, P<0.03) decreased respect to baseline, independently of glucose and HbA1c changes. Conversely, HDL cholesterol increased (1.16±0.28 vs 1.17±0.27 mmol/l, P<0.01). 35 patients left the study, 3 of them because of adverse effects.

Conclusion: Liraglutide is effective in controlling DM2 in daily clinical practice. Liraglutide could have pleiotropic actions in the control of DM2.